生物制药公司伊克力西斯（Exelixis Inc，股票代码：EXEL）今日盘中股价大涨9.66%，引发市场广泛关注。这一显著涨幅主要受益于公司强劲的财务业绩、上调全年收入预期以及分析师的积极评级。
根据公司最新公布的财报，伊克力西斯第一季度业绩表现亮眼，大幅超出市场预期。公司季度营收同比增长30.6%，达到5.5545亿美元，远高于分析师预期的4.9818亿美元。调整后每股收益（EPS）达到0.55美元，同样显著超过分析师平均预期的0.36美元。此外，公司本季度净收入为1.5962亿美元，展现出强劲的盈利能力。
更值得注意的是，伊克力西斯上调了2025年的收入预期，从此前的21.5亿至22.5亿美元上调至22.5亿至23.5亿美元。这一举措进一步增强了投资者对公司未来增长前景的信心。与此同时，华尔街投资银行TD Cowen今日将伊克力西斯的目标价从38美元上调至44美元，反映出分析师对公司发展前景的看好。这些积极因素共同推动了伊克力西斯股价的强劲上涨，展现出市场对该公司的高度认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.